Histogenics Corp. brought in more than $34 million in equity and debt financing after its acquisition of fellow Bay State firm ProChon Biotech Ltd.
The two companies merged in an all-stock deal that brings ProChon CEO Patrick O'Donnell into the Histogenics corner office.
O'Donnell told MassDevice.com last week that a deal has been in the works since the early part of 2011.